SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Firefly Aerospace, Inc. engages in the design and manufacture of space launch vehicles. The company was founded by Thomas E. Markusic, Mark Watt, and Max Polyakov in January 2017 and is headquartered in Leander, TX.

Firefly Aerospace Inc.

Fireflys large multiyear agreement with AST SpaceMobile to supply rocket engines, license propulsion technology and provide engineering support is driving attention, with traders viewing it as validation of the engine business and a major boost to contracted work. The sharp rally has prompted profit-taking and concerns about the deals stock component, funding terms and execution ahead of earnings.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricors pending FDA decision on deramiocel for Duchenne muscular dystrophy is the dominant focus, with traders debating whether HOPE-3 upper-limb results and a letter from physician-scientists will support approval or whether regulatory concerns could lead to rejection. Bullish positioning and short-squeeze speculation are prominent, but some traders emphasize the binary risk and uncertain outcome.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

Foxconn Tech Day photos and an industry researchers identification of a POET optical engine in FITs display have revived attention, with bulls viewing it as validation of POETs role in AI data-center optics while skeptics stress it is not proof of customer orders or scaled shipments. The new CFO appointment and upcoming earnings have also sharpened the debate over whether commercialization will translate into confirmed deliveries.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerrys QNX momentum is driving discussion, particularly Valeos smart-camera platform design wins with Chinese automakers and the broader QNXNvidia connection in automotive and robotics. Traders are bullish on the growth potential, while others question when partnerships will translate into revenue and whether the recent high-volume rally can hold; claims of short covering or institutional accumulation remain speculation.

Cornerstone Strategic Value Fund is a management investment company that is an investment operation. They limit the fund's investment in securities issued by other investment companies.

Cornerstone Strategic Investment Fund Inc.

Cornerstone Strategic Investment Fund, Inc.

Concern over Cornerstones rights-offering plans and falling NAV is weighing on CLM, with traders also anticipating a lower 2027 distribution because it is reset based on NAV. The community is divided between buying the weakness for the funds high monthly income and discounted DRIP shares, and trimming or exiting amid dilution and further share-price decline concerns.

Kodiak Sciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutics for retinal diseases. Its product pipeline includes KSI-301 for wet AMD, KSI-301 for diabetic eye disease, KSI-501 for DME and uveitis, KSI-201 for resistant wet AMD, and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.

Kodiak Sciences Inc

Positive Phase 3 DAYBREAK results for Kodiaks retinal-disease programs, alongside reported Baker Brothers share purchases, have fueled the stocks sharp run. Traders are split between optimism about the pipeline and institutional backing and concerns over valuation, cash needs, and possible dilution.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. It will generate domestically produced bitcoin powered by nuclear, hydro, and solar energy. It operates through the Digital Asset Mining and HPC Leasing segments. The company was founded by Paul B. Prager and Nazar M. Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulfs Q3 results and data-center outlook, alongside Googles credit support for financing tied to its Anthropic lease and a Fluor construction agreement, are driving attention. Bulls view the financing support as easing project risk, while skeptics point to construction, debt and broader AI-sector concerns; the reaction has been volatile.

Roku, Inc. engages in the provision of a streaming platform for television. It operates through the following segments: Platform and Devices. The Platform segment includes the sale of digital advertising and distribution of streaming services. The Devices segment is involved in the sale of streaming players, Roku-made televisions, smart home products and services, audio products, and related accessories. The company was founded by Anthony J. Wood in October 2002 and is headquartered in San Jose, CA.

Roku Inc - Ordinary Shares - Class A

Roku Inc

Foxs acquisition of Roku has closed, ending Rokus run as a standalone Nasdaq-listed company. Traders are marking the transition to Foxs streaming portfolio, with reactions ranging from farewells and frustration over the deal to optimism about combining Rokus platform with Tubi.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

ONDS is drawing attention amid a prolonged selloff despite new international counter-drone contracts and expansion plans; traders are debating whether upcoming earnings can show that its growing backlog is converting into results and ease concerns about dilution. Some attribute the weakness to broader pressure on drone and defense stocks, while others see the pullback as an opportunity.

XRP (XRP) is a cryptocurrency . XRP has a current supply of 99,985,583,260 with 63,516,606,953 in circulation. The last known price of XRP is 1.21896617 USD and is down -6.75 over the last 24 hours. It is currently trading on 1894 active market(s) with $2,821,731,810.20 traded over the last 24 hours. More information can be found at https://xrpl.org/.

Ripple

XRPs weak price action amid broader crypto-market volatility is driving discussion, with traders debating whether political uncertainty around the Clarity Act adds pressure. Bearish holders cite Ripples token supply and a lack of utility-driven demand, while others view the decline as a buying opportunity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$EIKN Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology Congress 
 
Eikon Therapeutics will present seven abstracts across its oncology pipeline at ESMO 2026, including updated Phase 2 data for EIK1001 in stage 4 NSCLC, updated Phase 1/2 data for EIK1003 in advanced solid tumors and metastatic prostate cancer, initial results for EIK1004 in advanced solid malignancies, and preliminary safety, tolerability and pharmacokinetic data for EIK1005, a WRN helicase inhibitor. The presentations span multiple early-stage programs targeting lung, prostate and other advanced cancers.

StockTwits Web

Eikon Therapeutics Inc.

 Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology Congress 
 
Eikon Therapeutics will present seven abstracts across its oncology pipeline at ESMO 2026, including updated Phase 2 data for EIK1001 in stage 4 NSCLC, updated Phase 1/2 data for EIK1003 in advanced solid tumors and metastatic prostate cancer, initial results for EIK1004 in advanced solid malignancies, and preliminary safety, tolerability and pharmacokinetic data for EIK1005, a WRN helicase inhibitor. The presentations span multiple early-stage programs targeting lung, prostate and other advanced cancers.